ADMA Biologics, Inc. (NASDAQ:ADMA) is at least 33.17% than its current record low price of $2.08. There was a 6.13% gain on 02/08/2019 that led the price to move at $2.77. At recent session, the prices were hovering between $2.56 and $2.86. This company shares are 276.17% off its target price of $10.42 and the current market capitalization stands at $120.99M. The recent change has given its price a -23.12% deficit over SMA 50 and -60.2% deficit over its 52-week high. The stock witnessed -19.01% declines, -49.54% declines and -54.66% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ADMA’s volatility during a week at 10.23% and during a month it has been found around 8.82%.ADMA Biologics, Inc. (ADMA) Top Holders
Institutional investors currently hold around $75 million or 58.9% in ADMA stock. Look at its top three institutional owners. Perceptive Advisors Llc owns $18.06 million in ADMA Biologics, Inc., which represents roughly 14.93% of the company’s market cap and approximately 24.08% of the institutional ownership. Similar statistics are true for the second largest owner, Consonance Capital Management Lp, which owns 4,539,295 shares of the stock are valued at $12.57 million. The third largest holder is Broadfin Capital, Llc, which currently holds $12.37 million worth of this stock and that ownership represents nearly 10.22% of its market capitalization.ADMA Biologics, Inc. 13F Filings
At the end of September reporting period, 32 institutional holders increased their position in ADMA Biologics, Inc. (NASDAQ:ADMA) by some 2,430,424 shares, 19 decreased positions by 1,304,504 and 12 held positions by 23,513,798. That puts total institutional holdings at 27,248,726 shares, according to SEC filings. The stock grabbed 5 new institutional investments totaling 101,680 shares while 4 institutional investors sold out their entire positions totaling 1,108,757 shares.ADMA Biologics, Inc. (NASDAQ:ADMA) Insider Trades
Multiple company employees have indulged in significant insider trading. ADMA Biologics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Richman Eric I has acquired 5,230 shares of ADMA Biologics, Inc. (ADMA) in trading session dated Jun. 08, 2018. These shares are worth $24,999 and were traded at $4.78 each. The SEC filing shows that Lenz Brian performed a purchase of 5,000 shares. The VP, CFO added these shares by way of transaction on Jun. 08, 2018. The company’s shares were assimilated at $4.78 per share worth to an investment of some $23,900 on account of Lenz Brian.
Director, Guiheen Lawrence P., purchased 20,000 common shares of ADMA Biologics, Inc. (ADMA) in the open market. In a transaction dated Jun. 08, 2018, the shares were bought at an average price of $4.78, giving away a sum of $95,600. After this purchase, 26,000 common shares of ADMA are directly owned by the insider, with total stake valued at $72,020.
In the transaction dated Jun. 08, 2018, the great number of shares acquired came courtesy the President and CEO; Grossman Adam S added a total of 73,222 shares at an average price of $4.78, amounting to approximately $350,001. The insider now directly owns 1,409,785 shares worth $3,905,105.ADMA Biologics, Inc. (ADMA) Analyst Guide
Several analysts have released their opinion on ADMA Biologics, Inc. (NASDAQ:ADMA), with 1 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 6 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.86 average brokerage recommendation.